Billionaire Bill Ackman Is Buying Microsoft Stock. Is It Still the Best Artificial Intelligence (AI) Buy Today?

Microsoft’s late-July results were well received, with 18% revenue and operating income growth and Azure cloud revenue up 43%, driving a sharp post-earnings rally. The key upside catalyst was that Microsoft did not increase full-year data center spending guidance (unlike other AI hyperscalers), lifting the valuation to ~25x forward earnings from <20x pre-earnings. While this removes much of the “bargain,” the article still frames the current price as fair and holding/adding selectively as reasonable given growth under 20% YoY.

Analysis

The market is treating this as a quality-vs-growth rerating problem, not a fundamentals surprise. At ~25x forward earnings, MSFT is now priced like a bond-proxy compounder, so the next leg up requires either another step-up in Azure monetization or a lower discount rate; neither is a high-conviction near-term catalyst. That makes the stock vulnerable to rotation into cheaper AI beneficiaries with more upside per unit of revenue growth, especially where valuation is still below historical premium despite similar AI exposure.

The second-order effect is on the rest of the mega-cap AI complex: if the leader can prove it does not need to keep ratcheting capex higher to preserve cloud growth, other hyperscalers will face a tougher burden of proof on return on invested capital. That is mildly negative for capex-linked beneficiaries over time, but it should not be confused with a near-term demand cliff; semiconductor spend can stay firm while the market simply stops paying up for every dollar of spend. In that setup, NVDA remains the cleaner “AI picks-and-shovels” expression versus MSFT because the market will likely reward higher growth more than platform maturity.

Contrarian risk: consensus may be underestimating how much operating leverage can still come from AI attached to existing enterprise software, which could justify a higher multiple if growth holds above 20% and free cash flow expands faster than revenue. The thesis breaks if the next 1-2 earnings cycles show Azure growth normalizing toward the high-20s/low-30s or if the market re-rates long-duration growth lower on rates. Over 6-18 months, the stock likely trades on multiple compression/expansion rather than earnings upside, so the opportunity cost of owning MSFT versus cheaper AI names is the real trade.

Key Decisions for Investors

• Prefer a relative-value rotation: underweight MSFT versus NVDA over the next 1-3 months; the setup favors the higher-beta growth name if AI spend stays resilient, with MSFT’s upside capped unless multiples expand back toward 30x.
• If already long MSFT, sell 1-2 month covered calls or trim into strength near the low- to mid-25x forward range; risk/reward is unfavorable above fair-value unless the next guidance cycle materially re-accelerates.
• Use MSFT as a hedge against AI exuberance only if the market starts paying for capex discipline instead of growth; otherwise, pair long NVDA / short MSFT for a relative-growth trade with a clear falsifier: Azure re-acceleration above current trajectory.
• Set an alert for the next earnings cycle: if MSFT keeps capex flat but Azure growth decelerates, expect multiple compression first; if revenue growth re-accelerates above 20% and FCF margin expands, the de-rating thesis fails.